the value of bispecifics in myeloma & the importance of optimally sequencing immunotherapies
Published 8 months ago • 16 plays • Length 1:27Download video MP4
Download video MP3
Similar videos
-
3:33
determining the optimal sequencing of bispecifics and car-t cells in patients with myeloma
-
4:02
an overview of bispecifics in r/r myeloma and their integration into the treatment landscape
-
1:33
sequencing and the management of adverse events when administering bispecifics for myeloma
-
4:14
defining primary refractory disease and its effect on patient outcomes in dlbcl
-
7:05
developments in the use of bispecific antibodies in myeloma and challenges in this space
-
5:06
bispecific antibodies: late side effects
-
4:04
the future of myeloma treatment and the possibility of cure
-
10:31
case study: discovery of biomarkers of immuno-oncology
-
2:38
approaching the treatment of patients with lbcl who relapse after bispecific antibodies
-
3:08
bispecifics part i: immune system and immunotherapy basics
-
2:16
the sequencing of novel therapies in myeloma (car-t, bispecifics, antibody-drug conjugates)
-
4:26
what are bispecific antibodies?
-
2:17
the role of car t-cell therapy for treating myeloma in the era of bispecific antibodies
-
4:58
novel immunotherapies transforming r/r myeloma treatment: bispecifics, car-t cells & more
-
0:51
the role of bispecifics in wm
-
3:37
bispecific antibodies in multiple myeloma: their current role and the future
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
1:06
feasibility of treatment with bispecifics in patients with myeloma with prior bcma exposure
-
2:22
outcomes and management of patients with r/r myeloma who progress on bispecific antibodies
-
1:45
the advent of bispecific antibodies for multiple myeloma
-
1:48
the potential of bispecific antibody-containing combinations in patients with b-cell lymphomas
-
6:35
the benefits of bispecific antibodies for treating multiple myeloma